Charles River Laboratories | CRL - Ebitda

Stock Price
173.03
Daily Change
3.23 1.90%
Monthly
4.30%
Yearly
50.91%
Q2 Forecast
166.17

Charles River Laboratories reported $258.06M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agilent USD 540M 74M Sep/2025
Align Technology USD 183.84M 19.77M Sep/2025
Bio-Rad Laboratories USD -374.6M 841.8M Sep/2025
Bruker USD 211.6M 207.4M Dec/2025
Cardinal Health USD 981M 5M Dec/2025
Charles River Laboratories USD 258.06M 24.83M Dec/2025
Cigna USD 2.86B 56M Mar/2025
CVS Health USD 3.74B 349M Dec/2025
Danaher USD 1.92B 204M Mar/2026
Dentsply International USD 135M 32M Dec/2025
Elevance Health USD 4.21B 2.02B Mar/2026
Galapagos EUR 2.42M 161.13M Sep/2025
Humana USD -290M 1.11B Dec/2025
Illumina USD 332M 12M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Intrexon USD -24.7M 2.92M Jun/2024
IQVIA Holdings USD 1.05B 97M Dec/2025
Laboratory Of America USD 588.1M 24.1M Dec/2025
Lonza CHF 1.01B 54M Dec/2025
McKesson USD 1.68B 418M Sep/2025
Merck EUR 1.44B 263M Dec/2025
Mettler Toledo International USD 322.64M 26.75M Sep/2025
Novartis USD 4.77B 1.11B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Quest Diagnostics USD 557M 20M Mar/2026
Revvity USD 248.91M 48.52M Dec/2025
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
United Therapeutics USD 379.5M 83.4M Dec/2025
UnitedHealth USD 9.99B 8.5B Mar/2026
Veradigm USD 38.81M 29.61M Sep/2022
Waters USD 380.97M 85.83M Dec/2025
West Pharmaceutical Services USD 226.2M 7.7M Mar/2026